Abstract：
BACKGROUND: Vasodilatation and bacterial dislocation are the main contributors to the catastrophic events in patients with decompensated liver cirrhosis (DLC).
OBJECTIVE: The aim of this study was to evaluate the impacts of adding midodrine and rifaximin on morbidity, mortality, and quality of life in patients with DLC.
METHODS: This interventional clinical study included 100 consecutively enrolled DLC patients randomized 1 : 1 into two groups. Group A received oral midodrine (5 mg/8 h) and rifaximin (550 mg/12 h) with standard diuretic therapy, while group B received only standard diuretic therapy. Clinical and laboratory data, including the McGill Quality of Life Questionnaire, were evaluated over a 3-month treatment period.
RESULTS: In the study group, there was a significant reduction in Child-Pugh and Model for End-Stage Liver Disease scores, international normalized ratio, and mean arterial blood pressure at 2, 6, and 12 weeks (P < 0.05). Ascites, spontaneous bacterial peritonitis incidence, hematemesis, paracentesis need, and hepatic encephalopathy showed improvement after 12 weeks compared with the control group. McGill Quality of Life Questionnaire significantly improved after 6 and 12 weeks (P < 0.05). Survival rates demonstrated a noteworthy improvement (P = 0.014), substantiated by evidence in both univariate and multivariate regression analyses.
CONCLUSIONS: Combined midodrine with rifaximin represents an endowment to patients with DLC with spectacular improvements in synthetic liver functions, along with improved quality of life, and survival.
OBJECTIVE: The aim of this study was to evaluate the impacts of adding midodrine and rifaximin on morbidity, mortality, and quality of life in patients with DLC.
METHODS: This interventional clinical study included 100 consecutively enrolled DLC patients randomized 1 : 1 into two groups. Group A received oral midodrine (5 mg/8 h) and rifaximin (550 mg/12 h) with standard diuretic therapy, while group B received only standard diuretic therapy. Clinical and laboratory data, including the McGill Quality of Life Questionnaire, were evaluated over a 3-month treatment period.
RESULTS: In the study group, there was a significant reduction in Child-Pugh and Model for End-Stage Liver Disease scores, international normalized ratio, and mean arterial blood pressure at 2, 6, and 12 weeks (P < 0.05). Ascites, spontaneous bacterial peritonitis incidence, hematemesis, paracentesis need, and hepatic encephalopathy showed improvement after 12 weeks compared with the control group. McGill Quality of Life Questionnaire significantly improved after 6 and 12 weeks (P < 0.05). Survival rates demonstrated a noteworthy improvement (P = 0.014), substantiated by evidence in both univariate and multivariate regression analyses.
CONCLUSIONS: Combined midodrine with rifaximin represents an endowment to patients with DLC with spectacular improvements in synthetic liver functions, along with improved quality of life, and survival.
摘要：
背景：血管扩张和细菌脱位是失代偿期肝硬化（DLC）患者灾难性事件的主要原因。
目的：本研究的目的是评估添加米多君和利福昔明对发病率的影响，死亡率,和DLC患者的生活质量。
方法：这项介入临床研究包括100名连续入选的DLC患者，按1：1随机分为两组。A组接受口服米多君（5mg/8h）和利福昔明（550mg/12h）以及标准利尿剂治疗，而B组仅接受标准利尿剂治疗。临床和实验室数据，包括麦吉尔生活质量问卷，在3个月的治疗期内进行评估。
结果：在研究组中，Child-Pugh和终末期肝病模型评分显着降低，国际标准化比率，2、6、12周平均动脉压（P<0.05）。腹水,自发性细菌性腹膜炎发病率，呕血,需要穿刺术，12周后肝性脑病较对照组改善。McGill生活质量问卷在术后6周和12周明显改善(P<0.05)。生存率显着改善（P=0.014），在单变量和多元回归分析中都有证据证实。
结论：米多君联合利福昔明代表了对DLC患者的禀赋，在合成肝功能方面有惊人的改善，随着生活质量的提高，和生存。
目的：本研究的目的是评估添加米多君和利福昔明对发病率的影响，死亡率,和DLC患者的生活质量。
方法：这项介入临床研究包括100名连续入选的DLC患者，按1：1随机分为两组。A组接受口服米多君（5mg/8h）和利福昔明（550mg/12h）以及标准利尿剂治疗，而B组仅接受标准利尿剂治疗。临床和实验室数据，包括麦吉尔生活质量问卷，在3个月的治疗期内进行评估。
结果：在研究组中，Child-Pugh和终末期肝病模型评分显着降低，国际标准化比率，2、6、12周平均动脉压（P<0.05）。腹水,自发性细菌性腹膜炎发病率，呕血,需要穿刺术，12周后肝性脑病较对照组改善。McGill生活质量问卷在术后6周和12周明显改善(P<0.05)。生存率显着改善（P=0.014），在单变量和多元回归分析中都有证据证实。
结论：米多君联合利福昔明代表了对DLC患者的禀赋，在合成肝功能方面有惊人的改善，随着生活质量的提高，和生存。
